Navigation Links
Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV,Activity

. Jenkins poster will be available for viewing at http://www.rigel.com after 11:00 a.m. PDT today.

Rigel's Rich Ligase Drug Discovery Program

Rigel is a leader in investigating and characterizing the ubiquitin ligase system for the discovery and development of potential new therapeutics. The company has initiated one of the industry's broadest efforts in working on the development of numerous ligase targets in oncology, inflammation, virology and metabolism. Rigel was one of the first companies to discover potent and highly selective small molecule inhibitors of ubiquitin ligases. Rigel has a broad- based platform in the enzymology and biology of ubiquitin ligases, which includes a large number of biochemical and cell-based assays to identify the specificity and selectivity of ligase targets. Rigel has an extensive patent portfolio covering the ligase area.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to Rigel's plans to pursue clinical development of product candidates and the timing thereof, and the potential ef
'"/>




Page: 1 2 3

Related medicine technology :

1. Rigel to Present New Research Programs at AACR Meeting
2. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
6. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
7. Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
8. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
9. CuraGen Presents Update on Clinical Development Program for Belinostat
10. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
11. Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program
Post Your Comments:
(Date:9/5/2008)...rom a Simple Blood Draw Have,the Potential to Serv...e of Indications,Usin... Currently Developing a Blood-Based ...JERSEY CITY, New Jersey, September 5,/PRNewswire-F... a leader in,the development of microRNA-based dia...
(Date:9/4/2008)...treatment of Acute Myeloid ...swire/ -- Celator Pharmaceuticals today,announced ... granted orphan,drug designation to CPX-351 (Cytar...atment of Acute Myeloid Leukemia (AML)., Celator ...hase 2,studies with CPX-351. The first Phase 2 stu...
(Date:9/4/2008)...R testing for the diagnostic ...ewswire/ -- The U.S. Food & Drug,Administration (F...Test,the first assay for quantitating Hepatitis B...e,s real-time PCR technology to quantify the amoun...octors may use viral load,testing results to estab...
(Date:9/4/2008)...ogists States UFE Meets Level,A Evidence for Clini...nal,Radiology Treatment Is Safe, Effective Option ...pt. 4 /PRNewswire-USNewswire/ -- The Society of,In... nearly 4,500 doctors,scientists and allied healt... through minimally invasive treatment intervention...
Breaking Medicine Technology:Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 2Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 4Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 2Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 3Beavers can help ease drought 2279 1Beavers can help ease drought 2279 2Music Therapy Improves Stroke Outcomes 12359 1Music Therapy Improves Stroke Outcomes 12359 2Grant to study if early BPA exposure leads to late prostate cancer 12355 1Grant to study if early BPA exposure leads to late prostate cancer 12355 2Standard test for blood sugar control not accurate in diabetic dialysis patients 12354 1Standard test for blood sugar control not accurate in diabetic dialysis patients 12354 2
...E)--Mar 12, 2007 - Ceragenix Pharmaceuticals,Inc.... on,infectious disease and dermatology, today anno...pound demonstrated virtually no biofilm,formation ...heters treated with Ceragenins,were soaked daily i...eated catheter. At day 21, the catheters were chal...
... March 12, 2007: Progen Industries Limited,(ASX: P...PI-88,Phase II liver cancer data has been accepted...an Association for the Study of the Liver,(EASL). ... liver,cancer trial at the American Association fo...In expectation of having final data fully analysed...
Other Medicine Technology:Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3
(Date:9/4/2008)...ate Medicare Advantage (MA) plans will be paid an ...pared to what the same enrollee would have cost in... according to a new report from The Commonwealth F...andated by the Medicare Improvements for Patients ...ke effect beginning in 2010 had been fully in pla...
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...d pancreatic tumors , , THURSDAY, Sept. ...iscoveries involving genetic mutations of two dead...ncreatic cancer -- may lead to new treatments and ...represent the most complete genetic analysis to da...c map of these deadly cancers," Kenneth Kinzler, a...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
Breaking Medicine News(10 mins):Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Genetic Mutations Linked to Deadly Cancers 2Health News:Genetic Mutations Linked to Deadly Cancers 3Health News:Genetic Mutations Linked to Deadly Cancers 4Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3
...during routine heel-prick or needle-stick blood te.../ Data from 1000 newborns in 11 studies was analy...st milk and breast-feeding was compared to a pacif...xperienced by infants when blood samples were take...
...care system to make doctors more accountable for t... Mary Harney said that the proposal includes vario...ommoners //on the Medical Council to 7 out of a to...e being introduced which would make it easy for th...
... man who suffered a burnt toe was ordered to under...of gangrene.// Derek Atkinson, 56, from Newton Ayc...a consultant at Bishop Auckland General Hospital. ...om a hot water bottle and since the symptoms seeme...
...sing exponentially in over-50s in Scotland causing...the rate// of sexually transmitted diseases had mo... Infections like chlamydia and herpes are also ri...tland. Health workers feel older citizens are ign...
Other Medicine News:Health News:Breast-fed Babies Experience Less Pain during Blood Tests 2
Cruciate Retaining, Posterior Stabilized and Constrained Components.
...bilized knee has an advanced design which provides...surfacing and inset patellas. Precision machined c...fit with tibial articular surface and patella to r...rovide easy intraoperative change of sizes. Increa...
StelKast's Proven knee system is a long term, quality solution based on a clinically proven design. Available in both posterior stabilized and anatomically correct cruciate retaining configurations.
The Foundation Knee CR System was designed to replicate normal knee kinematics. The patello- femoral joint has a recessed, deepened and extended patella groove to minimize advancement of the patella,
Medicine Products: